• Home  /
  • Healthcare   /
  • Insider selling: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Baity Glenn; EVP AND GC sold 26507 shares

Insider selling: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Baity Glenn; EVP AND GC sold 26507 shares

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) finished the trading with positive move of +1.54% and closed the day at $36.16 which had been above its previous day’s closing of $35.61.

Shares of the company registered a buying and selling volume of 1.4 million shares lower than its 3-months average volume of 1.45 million shares and traded in range of $35.13 to $36.57.

The firm has price to sales ratio of 69.20 and its price to book per share was 10.50. The stock is trading higher its 50-day moving averages of 31.14 and above 200-day moving averages of 31.78. The shares registered one year high of $40.83 and one year low was seen at $20.68.

Recent Insider Activity:

Currently the Insiders own 0.10% of ACADIA Pharmaceuticals Inc. shares. Institutional Investors own 99.20% of company’s shares. During last three month period, the net percent change held by Institutional Investors has seen a change of 0.28%. During last six month period, the net percent change kept by insiders has seen a change of -40.38%.

In the company’s insider trading activities, Baity Glenn; EVP AND GC of ACADIA Pharmaceuticals Inc. sold 26507 shares worth of $924315 in a transaction on 30 Aug 2017. In this transaction, these shares were sold at value of $34.87 per share, according to the information disclosed by the Securities and Exchange Commission in a Form 4 filing on 01 Sep 2017.

Baity Glenn; also sold 14322 shares worth of $499534 in a transaction dated on 09 Aug 2017. Shares were sold at the average price of 34.88 per share, according to SEC Form 4 filing submitted on 11 Aug 2017.

The following two tabs change content below.

Eldred Matthew

Eldred Matthew covers Healthcare Sector Company recent Press Releases news updates. He has three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a comment